Similar articles

• Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA.

  Zheng L, Wang W, Sun Q. Zheng L, et al. Signal Transduct Target Ther. 2024 Feb 20;9(1):46. doi: 10.1038/s41392-024-01770-y. Signal Transduct Target Ther. 2024. PMID: 38378623 Free PMC article. No abstract available.
• New drugs approved by the NMPA in 2024: Synthesis and clinical applications.

  Zhao X, Yuan L, Gong Z, Li M, Yuan Y, Geng J. Zhao X, et al. Eur J Med Chem. 2025 Jul 5;291:117643. doi: 10.1016/j.ejmech.2025.117643. Epub 2025 Apr 17. Eur J Med Chem. 2025. PMID: 40262297 Review.
• Clinical trial and performance evaluation of the Wantai HBsAg (CMIA) diagnostic kit for screening blood donors in China.

  Chen J, Wang F, Li J, Zuo Q, Wu D, Xiao C. Chen J, et al. Sci Rep. 2024 Feb 2;14(1):1891. doi: 10.1038/s41598-024-51910-1. Sci Rep. 2024. PMID: 38307913 Free PMC article. Clinical Trial.
• [China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition)].

  Chinese Association for Clinical Oncologists; Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care. Chinese Association for Clinical Oncologists, et al. Zhonghua Yi Xue Za Zhi. 2024 Feb 20;104(7):473-485. doi: 10.3760/cma.j.cn112137-20231013-00729. Zhonghua Yi Xue Za Zhi. 2024. PMID: 38317359 Chinese.
• Evolving drug regulatory landscape in China: A clinical pharmacology perspective.

  Tang W, Huang Y, Zhou D, Huang Y, Chen Y, Ren S, Li Y, Wu S, Zhao X, Song X, Wang H, Jin Y, Yu H, Zhang L, Li Y, Boulton D, Shen K. Tang W, et al. Clin Transl Sci. 2021 Jul;14(4):1222-1230. doi: 10.1111/cts.12987. Epub 2021 Feb 23. Clin Transl Sci. 2021. PMID: 33503308 Free PMC article. Review.